Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06250205 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
A Phase 1 study, sponsored by NewAmsterdam Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT06250205: Completed Phase 1 study, sponsored by NewAmsterdam Pharma.
NCT06250205 is a Phase 1 study that has completed, run by NewAmsterdam Pharma. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06250205, a Phase 1 study, has completed, sponsored by NewAmsterdam Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.
Primary Outcome
Plasma Cmax concentration of COC with and without Obicetrapib
Interventions
- DRUG Obicetrapib
- DRUG Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)
- DRUG Drospirenone / Ethinyl Estradiol (COC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2024-04-26 |
| Phase | Phase 1 |
What the finished NCT06250205 record still lists
NCT06250205 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 3 interventions - of which Obicetrapib is the first listed.
NCT06250205 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06250205 about?
NCT06250205 is a clinical study titled "Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib". A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.
What is the current status of trial NCT06250205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-02-05. Estimated completion is 2024-04-26.
What interventions are being tested in trial NCT06250205?
The interventions under investigation include: Obicetrapib (DRUG), Obicetrapib + Drospirenone / Ethinyl Estradiol (COC) (DRUG), Drospirenone / Ethinyl Estradiol (COC) (DRUG).
Who is sponsoring clinical trial NCT06250205?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06250205's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI